Qulipta will compete with BHVN’s Nurtec ODT, which is approved for both prevention and acute treatment (#msg-164076435, #msg-154072129).
ABBV now has three approved agents in its migraine portfolio: Qulipta; Ubrelvy (approved for acute treatment in 2019 [#msg-154072129]); and Botox. All three came to ABBV by way of Allergan.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.